Sandbox: ATL: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
Line 34: | Line 34: | ||
:* Etoposide {{and}} prednisone {{and}} vincristine {{and}} cyclophosphamide {{and}} doxorubicin (Dose-adjusted EPOCH) | :* Etoposide {{and}} prednisone {{and}} vincristine {{and}} cyclophosphamide {{and}} doxorubicin (Dose-adjusted EPOCH) | ||
:* Cyclophosphamide {{and}} vincristine {{and}} doxorubicin {{and}} dexamethasone (HyperCVAD) alternating with high-dose methotrexate and cytarabine | :* Cyclophosphamide {{and}} vincristine {{and}} doxorubicin {{and}} dexamethasone (HyperCVAD) alternating with high-dose methotrexate and cytarabine | ||
* Patients who do not respond to the initial chemotherapeutic regimens may be managed by other second line chemotherapeutic agents such as: | |||
:* Bendamustine | |||
:* Belinostat | |||
:* Brentuximab vedotin for systemic CD30+ PTCL | |||
:* DHAP (dexamethasone, cisplatin, cytarabine) | |||
:* ESHAP (etoposide {{and}} methylprednisolone {{and}} cytarabine {{and}} cisplatin) | |||
:* Dose-adjusted EPOCH | |||
:* GDP (gemcitabine {{and}} dexamethasone {{and}} cisplatin) | |||
:* GemOx (gemcitabine {{and}} oxaliplatin) | |||
:* ICE (ifosfamide {{and}} carboplatin {{and}} etoposide) | |||
:* Pralatrexated | |||
:* Romidepsin | |||
* Zidovudine and interferon combination therapy: | * Zidovudine and interferon combination therapy: | ||
:* Chronic/smoldering adult T-cell leukemia patients should be evaluated for response after two months of initiating the combination therapy. | :* Chronic/smoldering adult T-cell leukemia patients should be evaluated for response after two months of initiating the combination therapy. | ||
:* Patients who responded to the therapy may be further managed by either allogeneic stem cell transplantion or continue on zidovudine and interferon combination therapy. | :* Patients who responded to the therapy may be further managed by either allogeneic stem cell transplantion or continue on zidovudine and interferon combination therapy. | ||
:* While patients who did not respond to the therapy should be managed by either chemotherapy or supportive care depending on the patients preference. | :* While patients who did not respond to the therapy should be managed by either chemotherapy or supportive care depending on the patients preference. |
Revision as of 19:18, 25 January 2016
- The optimal therapy for adult T-cell leukemia depends on the clinical variant of the disease.
- Chronic and smoldering adult T-cell leukemia patients are usually managed by either observation, skin directed therapies, or a combination of idovudine and interferon therapy.
- Acute adult T-cell leukemia patients are usually managed by either chemotherapy, supportive care, allogeneic stem cell transplant, or a combination of zidovudine and interferon therapy.
- Adult T-cell lymphoma patients are usually managed by either chemotherapy, supportive care, or allogeneic stem cell transplant.
Management of Chronic/Smoldering Adult T-cell Leukemia
- Patients may be managed by observation and close follow-up for any symptomatic deterioration. Follow up tests for such patients may include:
- Complete history and physical examination
- Serum calcium level
- Blood urea nitrogen
- Serum creatinine level
- Serum LDH
- Chest and abdominal CT scan
- Skin directed therapies for the management of localized cutaneous lesions among such patients may include:
- Topical corticosteroids
- Topical chemotherapy (mechlorethamine)
- Local radiation (8–36 Gy)
- Topical retinoids (bexarotene, tazarotene)
- Phototherapy (UVB, NB-UVB for patch/thin plaques; PUVA for thicker plaques)
- Topical imiquimod
- Zidovudine and interferon combination therapy:
- Chronic/smoldering adult T-cell leukemia patients should be evaluated for response after two months of initiating the combination therapy.
- Patients who responded to the therapy should be continued on zidovudine and interferon therapy.
- While patients who did not respond to the therapy should be managed by either chemotherapy or supportive care depending on the patients preference.
- The criteria for complete remission of adult T-cell leukemia patients includes:
- Absence of lymphadenopathy
- Absence of hepatomegaly and splenomegaly
- Absence of cutaneous lesions
- Absence of malignant on peripheral blood smear
- Absence of malignant on bone marrow biopsy
Management of Acute Adult T-cell Leukemia
- The preferred chemotherapeutic regimens used for the initial management of adult T-cell leukemia include:
- Cyclophosphamide AND doxorubicin AND vincristine AND prednisone (CHOP)
- Cyclophosphamide AND doxorubicin AND vincristine AND etoposide AND prednisone (CHOEP)
- Etoposide AND prednisone AND vincristine AND cyclophosphamide AND doxorubicin (Dose-adjusted EPOCH)
- Cyclophosphamide AND vincristine AND doxorubicin AND dexamethasone (HyperCVAD) alternating with high-dose methotrexate and cytarabine
- Patients who do not respond to the initial chemotherapeutic regimens may be managed by other second line chemotherapeutic agents such as:
- Bendamustine
- Belinostat
- Brentuximab vedotin for systemic CD30+ PTCL
- DHAP (dexamethasone, cisplatin, cytarabine)
- ESHAP (etoposide AND methylprednisolone AND cytarabine AND cisplatin)
- Dose-adjusted EPOCH
- GDP (gemcitabine AND dexamethasone AND cisplatin)
- GemOx (gemcitabine AND oxaliplatin)
- ICE (ifosfamide AND carboplatin AND etoposide)
- Pralatrexated
- Romidepsin
- Zidovudine and interferon combination therapy:
- Chronic/smoldering adult T-cell leukemia patients should be evaluated for response after two months of initiating the combination therapy.
- Patients who responded to the therapy may be further managed by either allogeneic stem cell transplantion or continue on zidovudine and interferon combination therapy.
- While patients who did not respond to the therapy should be managed by either chemotherapy or supportive care depending on the patients preference.